Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy

Kidney International, Supplement

Volumn 66, Issue 92, 2004, Pages

  Alexander, Charles M ^a   Lyle, Paulette A ^a   Keane, William F ^a   Carides, George W ^a   Zhang, Zhongxin ^a   Shahinfar, Shahnaz ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Costs; Diabetic nephropathy; End stage renal disease

Indexed keywords

LOSARTAN; ANTIHYPERTENSIVE AGENT;

ALBUMINURIA; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST OF ILLNESS; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT OUTCOME; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETIC NEPHROPATHY; ECONOMICS; HEALTH CARE COST; RANDOMIZED CONTROLLED TRIAL; REVIEW; UNITED STATES;

ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HEALTH CARE COSTS; HUMANS; KIDNEY FAILURE, CHRONIC; LOSARTAN; UNITED STATES;

EID: 16644387097     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.09228.x     Document Type: Article

References (11)

1. U.S. RENAL DATA SYSTEM: USRDS 2001 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2001
2. HOSTETTER TH: Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 345:910-912, 2001
3. NISSENSON AR, RETTIG RA: Medicare's end-stage renal disease program: Current status and future prospects. Health Aff (Millwood) 18:161-179, 1999
4. U.S. RENAL DATA SYSTEM: USRDS 2000 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2000
5. BRENNER BM, COOPER ME, DE ZEEUW D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
6. DE ZEEUW D, REMUZZI G, PARVING HH, et al: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 65:2309-2320, 2004
7. HERMAN WH, SHAHINFAR S, CARIDES GW, et al: Losartan reduces the costs associated with diabetic end-stage renal disease: The RENAAL study economic evaluation. Diabetes Care 26:683-687, 2003
8. GERTH WC, REMUZZI G, VIBERTI G, et al: Losartan reduces the burden and cost of ESRD: Public health implications from the RENAAL study for the European Union. Kidney Int 62(Suppl 82):S68-S72, 2002
9. BURGESS ED, CARIDES GW, GERTH WC, et al: Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective. Can J Cardiol 20:613-618, 2004
10. KING H, AUBERT RE, HERMAN WH: Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 21:1414-1431, 1998
11. ISMAIL H, BECKER B, STRZELCZYK P, RITZ E: Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int 55:1-28, 1999